Results of Collagen Concentrate (UC-II) on Joint Pain and Inflammation Generating Better Results than Glucosamine, Chondroitin
Exciting supplement news for those searching for that product that helps relieve inflammation, joint pain or discomfort.
The results of a clinical study on patented collagen concentrate, were presented recently at the American College of Nutrition.
In a randomized, double-blind study of 52 patients, conducted in North America, one group took 40 mg patented collagen concentrate and the other a combination of glucosamine (1500 mg) + chondroitin (1200 mg).
Results of the studies and metrics showed a double-digit improvement by those using the collagen concentrate (trade name: UC-II) versus those using the most popular joint support and relief combination on the market – glucosamine and chondroitin.
The results show that patented collagen concentrate showed a significant improvement from baseline on all WOMAC* scores over the glucosamine + chondroitin combination. (WOMAC is the set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints.)
Both treatments reduced the WOMAC index score which measures the difficulty in physical function, stiffness and pain in the knee. However, treatment with patented collagen concentrate was found to be significantly more effective and reduced the WOMAC score by 33% compared to 14% in glucosamine plus chondroitin treated groups after 90 days.
Similar results were obtained for VAS (measure for acute and chronic pain. Although both the treatments reduced the VAS score, patented collagen concentrate was found to be most effective with 40% decrease after 90 days of treatment compared to 15.4% in glucosamine plus chondroitin treated groups.
The Lequesne’s functional index (assesses severity of osteoarthritis.) was used to determine the effect of different treatments on pain during daily activities. Treatment with patented collagen concentrate reduced Lequesne’s functional index score by 20.1% compared to 5.9 % in glucosamine plus chondroitin treated groups. Thus, the patented collagen concentrate treated group showed improvement in daily activities suggesting an improvement in quality of life.